Esketamine improves cognitive function in sepsis-associated encephalopathy by inhibiting microglia-mediated neuroinflammation.
Hui Li, Wen Hu, Zhen Wu, Bin Tian, Yimin Ren, Xiaohua Zou
European Journal of Pharmacology November 15, 2024 DOI: 10.1016/j.ejphar.2024.177014 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Mice with sepsis-associated encephalopathy |
| Interventions | Esketamine K252a |
| Topics | Esketamine |
| Keywords | Bdnf Microglia Sepsis-associated encephalopathy #neuroinflammation brain inflammation Neuro-immune response #esketamine ketamine #brainprotection neuroprotection Cognitive preservation |
| Citations | 11 |
| Key findings | Esketamine inhibits microglia-mediated neuroinflammation by activating the BDNF pathway, mitigating neuronal damage and cognitive dysfunction in mice with sepsis-associated encephalopathy. |
Abstract
Microglia-mediated neuroinflammation is critical in the pathogenesis of sepsis-associated encephalopathy(SAE). Identifying the key factors that inhibit microglia-mediated neuroinflammation holds promise as a potential target for preventing and treating SAE. Esketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, has been proposed to possess protective and therapeutic properties against neuroinflammatory disorders. This study provides evidence that the administration of Esketamine in SAE mice improves cognitive impairments and alleviates neuronal damage by inhibiting the microglia-mediated neuroinflammation. The BDNF receptor antagonist K252a was employed in both vivo and in vitro experiments. The findings indicate that K252a successfully counteracted the beneficial effects of Esketamine on microglia and cognitive behavior in mice with SAE. Consequently, these results suggest that Esketamine inhibits microglia-mediated neuroinflammation by activating the BDNF pathway, and mitigating neuronal damage and cognitive dysfunction associated with SAE.
Comparable studies
Other preclinical and animal studies on esketamine, most cited first.
Citations in the library
Cited by 3
- Effect of Esketamine on Postoperative Delirium and Inflammatory Response in Patients Undergoing Off-Pump Coronary Artery Bypass Grafting: A Randomized Controlled Study. Journal of Cardiothoracic and Vascular Anesthesia April 10, 2025
- Exploring Esketamine's Therapeutic Role for Perinatal Depression via TASK-1 Tandem Pore Potassium Channels. ACS Chemical Neuroscience July 29, 2025
- Esketamine alleviates neuroinflammation and cognitive impairment in male 3xTg-AD mice by regulating the TAOK1/IL-17 axis. Canadian journal of physiology and pharmacology January 1, 2026
Cites 2
- Esketamine ameliorates post-stroke anxiety by modulating microglial HDAC3/NF-κB/COX1 inflammatory signaling in ischemic cortex. European Journal of Pharmacology March 28, 2023
- Esketamine alleviates postoperative depression-like behavior through anti-inflammatory actions in mouse prefrontal cortex. Journal of Affective Disorders April 1, 2022